[ad_1]
BEIJING, July 19 (Xinhua) – Chinese scientists will begin the second phase of the clinical trial of an HIV vaccine on 160 volunteers, the China Daily reported on Friday.
The candidate vaccine, DNA-rTV, is based on replication of HIV DNA to boost effective immunization, according to Shao Yiming, chief HIV researcher at the China Center for Disease Control and Prevention, adding that 39, it was the first HIV vaccine of this type a second-phase clinical trial.
This vaccine under development, which contains HIV DNA segments instead of the complete human immunodeficiency virus, will have a more potent and lasting effect. It is also designed to target the most common HIV strains in China, Shao said.
More than 130 volunteers have been recruited so far and initial work is underway in one Beijing hospital and another in Hangzhou city, he added.
"It is hoped that the second phase trial will be completed in the second half of 2021 and that the third phase trial will begin at the end of the current year." Volunteers will participate in an attempt to test the effectiveness of the vaccine to protect people from HIV, "said Shao.
Source link
